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Abstract
Ulcerative colitis and Crohn’s disease represent the major groups of idiopathic 
disorders in inflammatory bowel disease (IBD). The etiology includes environmen-
tal factors, genetic factors, and immune responses. The pathogenesis is diversified; 
however, no guaranteed curative therapeutic regimen has been developed so far. 
This review contains information related to pathophysiology and current treatment 
options for IBD. It is known that IBD is caused by tissue-disruptive inflammatory 
reactions of the gut wall; that is why downregulation of the immune responses 
allows the healing of the damaged mucosa and allows the resetting of the physi-
ological functions of the gut back to normal. The main treatment options are still 
corticosteroids, immunomodulators, antibiotics, probiotics, and a series of new 
agents. Their effects include modulation of cytokines, neutrophil-derived factors, 
adhesion molecules, and reactive oxygen/nitrogen metabolites. The monoclonal 
antitumor necrosis factor as infliximab recombinant anti-inflammatory cytokines 
or related gene therapy is also used nowadays. Still, the fecal microbiota trans-
plantation (FMT) is considered to revolutionize the therapy in IBD, considering 
the abnormal inflammatory response due to the complicated relationship between 
microbiota and the immune system. It is imperative to mention the critical role dys-
biosis may have in the pathogenesis of IBDs. This review summarizes the available 
literature concerning the efficacy of FMT in IBDs.
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1. Introduction
The current manuscript represents an overview of literature reflecting the 
concern of gastroenterology physicians regarding the usefulness of fecal microbiota 
transplant as an appropriate and successful therapy in difficult to treat IBD patients. 
Inflammatory bowel disease (IBD) is a relapsing, remitting, and chronic disease 
that causes significant morbidity. The etiology of IBD is still unclear. The pheno-
type, the progression, and their development are multifactorial with environment 
and genetics. Nowadays, studies are confirming that the microbial influence in the 
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pathogenesis of IBD is increasing; this fact results from an inappropriate immune 
response towards components of the commensal microbiota. In IBD, the diversity 
of luminal microbiota is reduced. Firmicutes (bifidobacteria, lactobacillus, and 
Faecalibacterium prausnitzii) are especially decreased. On the opposite side, the 
mucosal adherent bacteria are increased [1, 2].
Both ulcerative colitis and Crohn’s disease share many common features like 
bloody stools, diarrhea, fever, and abdominal pain, but each of them also has unique 
features. There are many differences between the two entities, the most important 
being the depth of involvement in the bowel wall and their location. Crohn’s disease 
results in transmural ulceration of any portion of the gastrointestinal tract, but it 
affects most often the colon and terminal ileum; at the opposite side, ulcerative coli-
tis affects the rectum, but it may extend beyond the sigmoid and into the sigmoid or 
include the entire colon into the cecum [1–3].
2. Inflammatory bowel diseases
2.1 Etiology and pathophysiology
The etiology of IBD is not fully elucidated, but it seems that it often occurs in 
genetically susceptible individuals after an inappropriate immune response to the 
microbiota; so, the key to the pathogenesis of IBD is represented by the intestinal 
immune system. Typically, the gut epithelium prevents antigen or bacteria entry 
into the circulation by sealed intracellular junctions. In IBDs, because of the inflam-
mation or the loss of the primary barrier function, these intracellular junctions are 
defective. The Goblet cells produce mucus as an additional protective mechanism [4].
Crohn’s disease is a patchy inflammatory disease affecting any part of the 
digestive tract, from the mouth to the anus and perianal area. Ulcerative colitis is a 
disease of continuity involving the rectum and colon in a centripetal manner and 
associating extraintestinal involvement of the skin, bones, or eyes [5].
2.2 Histopathology
In the active form of IBD, the microscopic evaluation reveals the infiltration of 
lamina propria with a mix of macrophages, dendritic cells, neutrophils, and natural 
killer T cells. Because of the increased activation and number of these cells, there is 
also an increasing level of cytokines, interleukin 1b, tumor necrosis factor-alpha, 
and interleukin 23-TH 17 [6–8].
2.3 Clinical manifestations
Patients with ulcerative colitis describe tenesmus, abdominal pain, and a sensa-
tion of incomplete evacuation. Still, the most upsetting symptom is represented by 
bloody diarrhea with or without mucus. The physical exam reveals predominantly 
left upper or left lower quadrant abdominal pain [1].
Patients with Crohn’s disease have different clinical manifestations, depending on 
the region of gastrointestinal involvement. Symptoms like right lower quadrant pain, 
non-bloody diarrhea, and weight loss are the most common in Crohn’s disease [9].
2.4 Diagnosis
When diagnosing IBD, the clinician has to combine inflammatory laboratory 
markers, clinical findings, endoscopic biopsies, and imaging findings. The guiding 
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laboratory tests are represented by leukocytosis, microcytic anemia, thrombocytosis, 
and elevated levels of C-reactive protein and erythrocyte sedimentation rate [10–12].
The imagistic methods that are useful when diagnosing IBD or assessing 
 complications are ultrasound, magnetic resonance imaging (e.g., rectal fistulas), 
and computed tomography (e.g., perforation or bowel obstruction). But to confirm 
a diagnosis of IBD biopsies obtained via colonoscopy or esophagogastroduodenos-
copy is necessarily needed [12, 13].
2.5 Options of treatment
There are many conventional and novel drug treatments that have proven effi-
cacy in IBDs (aminosalicylates, steroids, biological therapies, and immunosuppres-
sants). However, many patients become refractory to standard management of the 
disease, some of them presenting significant side effects that even require surgery. 
There are an increasing number of patients that live with mild active symptoms, 
despite medical treatment, having a poor quality of life [14–16].
The gastrointestinal microbiota has a dominant role in driving inflammation in 
IBD; that is why medications that manipulate the microbiota have been investigated 
(e.g., probiotics, prebiotics) with variable evidence of their efficacy [15, 16].
Alternative treatment in IBD management is fecal microbiota transplantation 
(FMT) consisting of the transfer of gut microbiota from a healthy donor, via infu-
sion of a liquid stool suspension, to restore the intestinal microbiota of a diseased 
person. This therapy procedure was firstly documented in 1958 [17].
The reports concerning the patients that have been subjected to fecal microbiota 
transplantation had positive outcomes [18–20].
3. Microbiota
In humans, the gut microbiota varies across the digestive tract. There are rela-
tively few bacterial species present in the stomach and small intestine, compared 
to the colon, which is the habitat of the highest microbial density—up to 1012 cells 
per gram of intestinal content. Ninety-nine percent of the bacteria are anaerobes, 
except the cecum, where aerobic bacteria achieve high frequencies [21].
Although many species in the human gut have not been studied because they 
cannot be cultured by the ways yet discovered, there are four dominant phyla: 
Proteobacteria, Bacteroidetes, Actinobacteria, and Firmicutes. Most bacteria belong to 
the genera Bifidobacteria, Clostridium, Peptostreptococcus, Bacteroides, Peptococcus, 
Ruminococcus, Eubacterium, and Faecalibacterium [22, 23].
3.1 Normal functions
The gut microbiota is still intensively studied. Besides metabolizing indigestible 
food compounds, it stimulates the gut immune system, directly defending against 
pathogens. It has a substantial role in developing and maintaining the intestinal 
epithelium and inducing antibody production. Also, studies focused on its action in 
the gut-brain axis [23, 24].
3.1.1 Direct inhibition of pathogenic bacteria
The intestinal barrier provides protection against pathogenic invasion through 
many defense mechanisms, including butyrate and other metabolically protective 
products, the commensal bacteria competitively preventing pathogenic bacteria’s 
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colonization. Disruption of intestinal barrier function may cause local or even sys-
temic immune over-response, afferent vagus nerve activation, neuroinflammation, 
and mast cell degranulation. Furthermore, some species of the commensal bacteria, 
like Lactobacillus plantarum, binds and stimulates the Toll-like receptor 2 (TLR2) in 
the intestinal epithelium, thus maintaining epithelial integrity [24–26].
3.1.2 Development of the immune system
The human intestinal flora develops in the first 2 years after birth, when the 
intestinal epithelium and mucosal barrier evolve in a tolerant and even in a support-
ive manner. Particularly, goblet cells—the ones producing the mucosa—proliferate, 
resulting in a thickening of the mucosa layer in which commensal bacteria may 
anchor and feed but cannot penetrate. Furthermore, the gut-associated lymphoid 
tissue, which is part of the gut epithelium, has a role in detecting and reacting to 
pathogens, being tolerant of commensal species and its metabolites and digestive 
products of food [26–29].
Cytokines stimulate the immune system to produce inflammation to protect 
itself, which may decrease the immune response to control homeostasis and favor 
healing after injuries. There is some bacterial species in the intestinal flora which 
seems to drive the production of selective cytokines by the immune system, such as 
Bacteroides fragilis and Clostridium species, which may induce an anti-inflammatory 
response, although some segmented filamentous bacteria cause the production of 
inflammatory cytokines [29, 30].
Another function of the intestinal flora is driving the immune system to produce 
antibodies. Thus, B cells switch class to IgA in another way, normally needing 
activation from T helper cells. Intestinal epithelial cells induce NF-kB signaling, 
which causes the secretion of further signaling molecules. These interact with B 
cells and induce the switching class to IgA—an important type of antibody because 
it keeps healthy a mucosal environment by eliminating the microorganisms that 
cause inflammatory responses [24, 25].
Gut flora can produce metabolites that can affect cells in the immune system, 
such as short-chain fatty acids produced through fermentation, and can induce 
an increased production of eosinophils, neutrophils, and basophils, which are 
components of the innate immune system and have a role in limiting the infection’s 
spreading [26].
3.1.3 Metabolism
The intestinal flora is essential for digestion through some enzymes that the 
human body does not possess to break down polysaccharides. Carbohydrates are 
turned into short-chain fatty acids by saccharolytic fermentation, including acetic 
acid, propionic acid, and butyric acid, used by the host cells as a source of energy 
and nutrients. Also, gut flora facilitates the absorption of minerals—magnesium, 
calcium, iron—and synthesizes vitamins, biotin and folate [27].
3.1.4 Microbiome-gut-brain axis
The microbiome-gut-brain axis includes the central nervous system and the 
neuroendocrine and neuroimmune systems, hypothalamic–pituitary–adrenal axis, 
sympathetic and parasympathetic arms of the autonomic nervous system, the 
enteric nervous system, the vagus nerve, and the intestinal microbiota [28].
The term refers to the biochemical signaling between the central nervous system 
and the gastrointestinal tract [29].
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3.2 Dysbiosis
Dysbiosis represents microbial imbalance or maladaptation that can be caused 
by many triggers, such as antibiotic treatments, alcohol abuse, or inappropriate 
diet. Also, microorganisms present in the digestive tract may contribute to inflam-
matory disorders, or specific metabolites influence some signaling pathways leading 
to obesity and colon cancer. Additionally, sepsis may occur in cases of breaking 
down of the intestinal epithelium with the invasion of flora components into host’s 
compartments [30, 31].
4. Fecal microbiota transplant (FMT)
4.1 General considerations
The new key in treating dysbiosis is the fecal microbiota transplant, which 
restores colonic microflora. It involves the transplantation of fecal bacteria from a 
healthy individual by colonoscopy, enema, orogastric tube, or orally by capsules 
containing freeze-dried material. FMT has been used in treating Clostridium dif-
ficile infection and experimentally in inflammatory bowel disease, irritable bowel 
syndrome, constipation, and some neurological conditions, like multiple sclerosis 
and Parkinson’s disease [32].
The size of samples has to range from 30 to 100 grams of fecal material for 
the treatment to be effective. The fresh stool is needed to increase the viability of 
bacteria, and samples are prepared within 6–8 hours, diluted with 2.5–5 times the 
sample’s volume with normal saline, sterile water, or 4% milk [32, 33].
The donor selection is strict and involves screening of medical history, screen-
ing for chronic diseases, and laboratory testing for pathogenic gastrointestinal 
infections [33].
However, clinical trials report cases of important adverse events after fecal 
microbiota transplant, such as gram-negative bacteremia combined with aspira-
tion pneumonia or even toxic megacolon. Adverse events are the reason why 
the FDA decided to expand donor-stool screening by including tests for human 
T-lymphotropic virus, norovirus, and extended-spectrum beta-lactamase-pro-
ducing microorganisms. Also, to minimize the risk of infection, clinicians should 
forget the “one size fits all” approach and consider the risks and benefits for each 
individual, especially in cases of immunocompromised patients [34–36].
The process of choosing donors include four stages as follows: stage 1, eliminat-
ing overweight (body mass index >30) patients, smokers, and those unable to 
donate periodically; stage 2, eliminating donors with microbiome-associated condi-
tions, such as metabolic, gastrointestinal, autoimmune, allergic, atopic, neurologic, 
and psychiatric; stage 3, stool and nasal screening, involving tests for antibiotic-
resistant bacteria; and stage 4, blood tests [35, 36].
We can conclude that healthy donors are hard to find. Thus clinicians should 
continue improving donor screening to reduce drug-resistant microorganisms 
transmission, and research should focus on the benefits and the risks involved in 
fecal microbiota transplant [37].
4.2 FMT in inflammatory bowel disease
It is mandatory to mention the important role that dysbiosis may have in the 
pathogenesis of inflammatory bowel disease, considering the abnormal inflamma-
tory response resulted from the complex relationship between microbiota and the 
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immune system. This feature is the reason why ongoing research carries so much 
interest in correcting dysbiosis using fecal microbiota transplantation [37, 38].
FMT can reduce IBD’s severity by increasing the production of short-chain fatty 
acids (butyrate); this way, the bowel permeability is reduced, and the integrity of 
the gut epithelium is maintained. Also, inhibiting the production of inflammatory 
elements, leukocyte adhesion, and the activity of T cells, FMT may restore the 
immune system [38].
In patients with ulcerative colitis and Crohn’s disease, preliminary  clinical 
studies showed a long-term follow-up clinical remission maintained, even endo-
scopic and histologic remission in a few other cases. A meta-analysis of nine 
studies showed a remission rate of 36.2%. Still, the results depend on some factors 
like age (higher remission in younger patients with ages between 7 and 20 years 
old), route of administration (naso-jejunal tube, enema, colonoscopy), and dose 
and preparation of donor feces. Also, it seems like fecal microbiota transplant is 
more effective in Crohn’s disease than in ulcerative colitis with remission rates 
of 60.5 and 22%, respectively. On the other hand, a study involving 15 patients 
with steroid-dependent ulcerative colitis who received fecal microbiota trans-
plant through colonoscopy showed a long-term maintained remission in 57% of 
cases [38–40].
Because of the lack of uniformity regarding the treatment protocols and the 
delivery method, it is hard to offer a solid conclusion referring to the safety and 
efficacy of fecal microbiota transplant in inflammatory bowel disease. If compared 
with the results collected in cases of recurrent Clostridium difficile infection (remis-
sion in about 90%), these results may look discouraging. Still, we have to keep in 
mind that the inflammatory bowel disease’s pathogenesis is not purely driven by 
dysbiosis as it happens in Clostridium difficile infection. Following this direction, we 
need more randomized controlled placebo studies to clarify the role of fecal micro-
biota transplant in inflammatory bowel disease [40–42].
4.3 Potential adverse effects of FMT
These can be classified into short-term and long-term side effects [19].
Short-term side effects are related to the delivery method. They may include 
mild fever, flatulence, constipation, diarrhea, vomiting, and abdominal discomfort, 
but all of these usually resolve in a few weeks. In cases when FMT was administered 
through the naso-jejunal tube, patients presented with high fever and the rise of 
the C-reactive protein. When using colonoscopy, there have been reported cases of 
perforation, bleeding, and symptoms related to anesthesia [43].
Due to the lack of research, there are few data collected about the dominant 
concern regarding the safety of fecal microbiota transplant—long-term side effects. 
We can speculate a considerable risk for chronic diseases, involving obesity, diabe-
tes, colon cancer, and atherosclerosis, due to the alteration of intestinal microbiota 
[43, 44].
5. Conclusions
Inflammatory bowel diseases are chronic, relapsing intestinal disorders, with 
pathogenesis not fully elucidated. Treatment disappointments are still high, despite 
the availability of different therapeutic options. Patients’ reduced compliance, the 
impoverished life of quality, and the increased economic, sanitary, and social burden 
worldwide are still unresolved issues. For that reason, research must continue to 
identify more information about the intestinal microbiota, metabolic pathways, and 
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